Neuroaxonal Dystrophy is characterized by the development of abnormal swellings within nerve fibers, known as axonal spheroids. These abnormalities disrupt the transmission of nerve signals throughout the body, resulting in progressive neurological impairment. Because NAD-TECPR2 is an inherited condition, affected dogs receive the mutated gene from their parents, making genetic testing a valuable tool for identifying carriers and reducing the risk of producing affected puppies.
Clinical signs of NAD-TECPR2 typically develop during puppyhood or early adulthood, although the age of onset and severity can vary. Early symptoms may be subtle and can include mild coordination problems, an unsteady gait, or difficulty performing routine movements. As the disease progresses, affected dogs may develop more pronounced neurological abnormalities such as hind limb weakness, stumbling, loss of balance, tremors, muscle wasting, abnormal posture, reduced reflexes, and difficulty standing or walking. In advanced stages, mobility can become severely compromised, significantly affecting the dog's quality of life.
The NAD-TECPR2 DNA Health Test is designed to identify the specific genetic mutation associated with this inherited neurological disorder. Testing is simple and non-invasive, requiring either a cheek swab or blood sample. The sample is analyzed in a specialized laboratory to determine the dog's genetic status. Since DNA remains unchanged throughout life, testing can be performed at any age, including in puppies before clinical signs appear.
Results are generally reported in one of three categories:
- Clear (Normal): The dog does not carry the NAD-TECPR2 mutation and cannot pass it to offspring.
- Carrier: The dog carries one copy of the mutation but is typically unaffected by the disease. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and has a significantly increased likelihood of developing Neuroaxonal Dystrophy.
Genetic testing for NAD-TECPR2 provides valuable information for breeders, veterinarians, and dog owners. Breeders can use test results to make informed mating decisions that help reduce the prevalence of the disorder while preserving healthy genetic diversity within the breed population. Avoiding the breeding of two carrier dogs can significantly reduce the risk of producing affected offspring.
For dog owners, knowledge of a dog's genetic status allows for proactive health monitoring and early veterinary evaluation. Dogs identified as at risk can benefit from regular neurological assessments and supportive care aimed at maintaining comfort and mobility. Although there is currently no cure for Neuroaxonal Dystrophy, early diagnosis can help guide management strategies and improve overall quality of life.
The Neuroaxonal Dystrophy (NAD-TECPR2) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine neurological health, and helps reduce the impact of this inherited neurodegenerative disorder. Through early detection and informed breeding decisions, breeders and owners can contribute to healthier future generations of dogs and improved long-term welfare.
